Design of the Efficacy of Prednisone in the Treatment of Ocular Myasthenia (EPITOME) trial

Michael Benatar, Donald B. Sanders, Gil I. Wolfe, Michael P. McDermott, Rabi Tawil

Research output: Contribution to journalArticle

22 Scopus citations


Efficacy of Prednisone in the Treatment of Ocular Myasthenia (EPITOME) is a multicenter, randomized, double blind, placebo-controlled trial that is being conducted under the auspices of the Muscle Study Group. EPITOME is the first randomized control trial in patients with ocular myasthenia and aims to evaluate the efficacy and tolerability of prednisone over a period of four months in patients with newly diagnosed ocular myasthenia whose symptoms have failed to remit in response to a trial of cholinesterase inhibitor therapy.

Original languageEnglish (US)
Pages (from-to)17-22
Number of pages6
JournalAnnals of the New York Academy of Sciences
Issue number1
StatePublished - Dec 2012



  • Clinical trial
  • Evidence-based medicine
  • Ocular myasthenia
  • Steroids

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • History and Philosophy of Science

Cite this